Investment
Features
FeesSafety
Academy
More
Pluang+

BNB nears $800 but faces resistance, retreating to $782; key support at $750-$760 holds rally potential.

Technical Signals
23 Sep 2026
AMBCrypto
View Source
Neutral
BNB nears $800 but faces resistance, retreating to $782; key support at $750-$760 holds rally potential.

BNB cryptocurrency almost reached the $800 price level, peaking at $799.67 before sellers caused a pullback to around $782. This resistance at $800 is now a critical barrier that buyers need to overcome to confirm further gains. Despite the retreat, BNB remains above key support levels between $750 and $760, which could sustain the recent rally if buyers defend this range. The market is closely watching whether buyers can maintain support and attempt another push past $800.

BNB coin price action provides context for cryptocurrency market dynamics. For readers following crypto, here is Pluang's market snapshot as of Sep 23, 2026 22:05 WIB: out of 50 major cryptocurrencies, 14 rose and 35 fell today. Notable movers include BAL (Balancer) with a 1-day change of +11.14% at Rp16.297 and GRT (The Graph) with +10.50% at Rp469.

More News

GE Aerospace stock could rise 35% as analysts highlight strong backlog and new engine orders.

GE Aerospace stock could rise 35% as analysts highlight strong backlog and new engine orders.

Jefferies analysts set a new price target of $435 for General Electric Aerospace, implying a 35% upside from its current price of around $321. GE Aerospace's strong position is supported by a $170 billion commercial services backlog and 80,000 aircra...

Analyst Insights
Bullish
1 hour ago
BNP Paribas cuts PepsiCo price target to $161, citing demand challenges but keeps Outperform rating.

BNP Paribas cuts PepsiCo price target to $161, citing demand challenges but keeps Outperform rating.

BNP Paribas lowered its price target for PepsiCo from $183 to $161 on September 23, 2026, due to ongoing demand challenges in North America. Despite the cut, the firm maintained an Outperform rating, indicating confidence in the stock's potential. Th...

Analyst Insights
Bearish
2 hours ago
Celldex's price target jumps to $88 after positive Phase III trial for chronic urticaria drug.

Celldex's price target jumps to $88 after positive Phase III trial for chronic urticaria drug.

Celldex Therapeutics saw its price target raised from $70 to $88 by Leerink Partners following successful Phase III trial results for its drug barzolvolimab treating chronic spontaneous urticaria (CSU). The trials met all primary endpoints, showing l...

Analyst Insights
Bullish
2 hours ago
Ero Copper stock holds steady with a raised price target amid plans to boost production by 2028.

Ero Copper stock holds steady with a raised price target amid plans to boost production by 2028.

Ero Copper, a major copper producer, shows stock volatility between $16.88 and $40.83 over the past year. Analyst firm CIBC maintained a "Neutral" rating but increased the price target to C$56.00, reflecting optimism about the company's long-term gro...

Analyst Insights
Bullish
2 hours ago
Cintas reports strong Q1 with EPS $1.39 and revenue up 10.9%, beating estimates.

Cintas reports strong Q1 with EPS $1.39 and revenue up 10.9%, beating estimates.

Cintas Corporation posted robust first-quarter results, surpassing analyst expectations with earnings per share of $1.39 and revenue of $3.01 billion, a 10.9% increase year-over-year. The company's organic revenue growth was 8.9%, reflecting solid bu...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App